FR941128-1-00016 FR941128-1-00002 DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration 21 CFR Parts 20, 310, 312, 314, and 600 [Docket No. 93N&hyph;0181] Adverse Experience Reporting Requirements for Human Drug and Licensed Biological Products; Correction AGENCY: Food and Drug Administration, HHS. ACTION: Proposed rule; correction. SUMMARY: The Food and Drug Administration (FDA) is correcting a proposal that appeared in the Federal Register of October 27, 1994 (59 FR 54046). That document proposed to amend FDA's current adverse experience reporting regulations for human drugs and biological products. The document was published with two errors. This document corrects those errors. FOR FURTHER INFORMATION CONTACT: Howard P. Muller, Center for Drug Evaluation and Research (HFD&hyph;362), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301&hyph;594&hyph;1049. SUPPLEMENTARY INFORMATION: In FR Doc. 94&hyph;26483 appearing on page 54046 in the Federal Register of October 27, 1994, the following corrections are made: 1. On page 54059, in the third column, under amendment 15, in the ninth line the words ``the second sentence in paragraph (d)(1)'' are corrected to read ``the third sentence in paragraph (d)(1)''. ยง314.80 [Corrected] 2. On page 54061, in the third column, in ยง314.80 Postmarketing reporting of adverse drug experiences , in paragraph (d)(1), in line 8, the words ``either as case reports or as the result of a formal clinical trial'' are corrected to read ``either as the result of a formal clinical trial, or from epidemiological studies or analyses of experience in a monitored series of patients.'' Dated: November 18, 1994. William K. Hubbard, Interim Deputy Commissioner for Policy. [FR Doc. 94&hyph;29114 Filed 11&hyph;25&hyph;94; 8:45 am] BILLING CODE 4160&hyph;01&hyph;F
